Natixis Advisors LLC Acquires 20,050 Shares of Charles River Laboratories International, Inc. $CRL

Natixis Advisors LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 23.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 104,960 shares of the medical research company’s stock after buying an additional 20,050 shares during the quarter. Natixis Advisors LLC owned about 0.21% of Charles River Laboratories International worth $16,422,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in CRL. Vanguard Group Inc. boosted its holdings in Charles River Laboratories International by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock worth $913,686,000 after acquiring an additional 27,989 shares in the last quarter. Ariel Investments LLC raised its holdings in Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after buying an additional 314,572 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Charles River Laboratories International by 11.6% during the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after buying an additional 128,785 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Charles River Laboratories International by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock worth $176,909,000 after acquiring an additional 120,207 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Charles River Laboratories International by 29.2% in the 2nd quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company’s stock valued at $155,677,000 after acquiring an additional 232,020 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL opened at $168.88 on Thursday. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $228.88. The company has a market cap of $8.31 billion, a price-to-earnings ratio of -57.05, a price-to-earnings-growth ratio of 2.86 and a beta of 1.64. The stock has a fifty day simple moving average of $193.48 and a two-hundred day simple moving average of $181.14. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.06. The company had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of a number of analyst reports. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Citigroup lifted their price target on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 16th. TD Cowen decreased their target price on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Finally, Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, December 15th. Ten research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.